Author: Antonio Gonçalves; Julie Bertrand; Ruian Ke; Emmanuelle Comets; Xavier de Lamballerie; Denis Malvy; Andrés Pizzorno; Olivier Terrier; Manuel Rosa Calatrava; France Mentré; Patrick Smith; Alan S Perelson; Jérémie Guedj
Title: Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load Document date: 2020_4_7
ID: n6l2804j_2
Snippet: Despite the unprecedented mobilization of the clinical and scientific community, the 57 development and large scale implementation of new antiviral drugs or vaccines will take 58 months or more. To readily propose a first line of defense and combat the virus in hospitalized 59 patients, the World Health Organization relies on already existing drugs ("repurposed") that 60 are immediately available in large quantities and have a good safety profile.....
Document: Despite the unprecedented mobilization of the clinical and scientific community, the 57 development and large scale implementation of new antiviral drugs or vaccines will take 58 months or more. To readily propose a first line of defense and combat the virus in hospitalized 59 patients, the World Health Organization relies on already existing drugs ("repurposed") that 60 are immediately available in large quantities and have a good safety profile. In coordination 61 with other European institutions, France is implementing a randomized clinical trial in 62 hospitalized patients ("DisCoVery", NCT04315948) comparing the efficacy of 63 lopinavir/ritonavir ± IFN-β-1a, remdesivir and hydroxychloroquine. Given the very limited 64 knowledge of the host/pathogen interaction the clinical efficacy of treatment strategies using 65 these drugs is largely unknown and could be limited [1] . 66
Search related documents:
Co phrase search for related documents- antiviral drug and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- antiviral drug and defense line: 1, 2, 3
- antiviral drug and good safety profile: 1, 2, 3
- antiviral drug and host pathogen: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral drug and host pathogen interaction: 1
- antiviral drug and hydroxychloroquine remdesivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- antiviral drug and large scale: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- antiviral drug and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- antiviral drug and new antiviral drug: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antiviral drug and repurpose drug: 1, 2
- antiviral drug and safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- antiviral drug and scientific clinical community: 1
- antiviral drug and treatment strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- antiviral drug and vaccine new antiviral drug: 1, 2, 3, 4
- antiviral drug and virus combat: 1, 2, 3, 4, 5, 6, 7
- clinical efficacy and defense line: 1
- clinical efficacy and good safety profile: 1, 2, 3, 4, 5, 6
- clinical efficacy and host pathogen: 1, 2, 3
- clinical efficacy and host pathogen interaction: 1
Co phrase search for related documents, hyperlinks ordered by date